Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

Marius Pharmaceuticals and Hims & Hers™ collaborate to expand access to KYZATREX® (testosterone undecanoate) CIII capsules, the first FDA-approved oral testosterone therapy available on the Hims & Hers platform

testosterone levels. In a clinical study, KYZATREX was proven to be up to 96% effective at restoring testosterone levels.1-3* On average, free testosterone doubled, giving study participants higher amounts of bioavailable testosterone.2,3 Higher...

Waldencast announces the FDA approval of Obagi® saypha® MagIQ™ injectable hyaluronic acid gel under the Obagi Medical brand

innovator in aesthetics, doubling Obagi Medical’s total addressable market to approximately $4.2 billion by 2029.1 “This milestone represents an exciting advancement in our long-term strategy to become the world’s leading dermatological megabrand...

At World Sleep 2025, Avadel Pharmaceuticals will present new data on LUMRYZ™ (sodium oxybate) for extended-release oral suspension

that new data supporting the use of LUMRYZ as a narcolepsy treatment will be presented in one oral presentation and 16 posters at World Sleep 2025, taking place September 5-10, in Singapore. "LUMRYZ's novel once-nightly delivery system means...

Nuvation Bio unveils new data on IBTROZI™ (taletrectinib) in advanced ROS1-positive non-small cell lung cancer

studies evaluating IBTROZI™ (taletrectinib) for the treatment of adult patients with locally advanced or metastatic ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC). “With additional follow-up time, these updated findings from the TRUST...

In the IDeate-Lung01 Phase 2 trial, Ifinatamab Deruxtecan demonstrated clinically meaningful response rates in patients with extensive-stage small cell lung cancer

Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were...

Precision BioSciences announces a U.S. patent covering PBGENE-HBV for chronic hepatitis B and provides updates on the program's status

develop in vivo gene editing therapies for diseases with high unmet need, announced that it will be issued U.S. Patent No. 12,410,418 by the U.S. Patent and Trademark Office on September 9, 2025, titled “Optimized engineered meganucleases having...

Boehringer Ingelheim launches swine vaccine with advanced protection against Porcine Circovirus Type 2 in the U.S

has observed a clear shift over the past decade, with PCV2d becoming the predominant genotype in the U.S. and globally.1,2 The broad protection provided by INGELVAC CIRCOFLEX® AD was designed with this shifting landscape in mind, advancing pig...

Experic appoints Jeffrey Shane as Chief Commercial Officer

strategic equipment partner. He has also been a member of Experic’s Board of Directors since the company’s launch in 2018. “We are delighted to welcome Jeffrey into this role,” said David Wood, Chairman & CEO of Experic. “His distinguished career...

Mytos announces partnerships with StemSight, Rinri Therapeutics, and Novadip to drive next-generation cell therapy trials

Mytos’ automation to support the production of their otic neural progenitor cell therapy. “As our lead product, Rincell-1 for sensorineural hearing loss, enters the clinic, manufacturing precision and consistency are critical,” said Dr. Terri...

Eisai submitted a rolling sBLA to the U.S. FDA for LEQEMBI® IQLIK™ as a subcutaneous starting dose to treat early Alzheimer’s, under Fast Track status

across a range of doses and as part of sub-studies within the Phase 3 Clarity AD open-label extension (OLE), following the 18-month core study in individuals with early AD. Should the FDA approve the LEQEMBI IQLIK 500 mg SC dosing regimen (two 250...

Sai Life Sciences afslutter fase II af produktionsblok 11 på Bidar-stedet i Indien og øger kapaciteten til 700 KL

and Manufacturing Organization (CRDMO), today announced the completion of Phase II of its new Production Block (PB-11) at the company’s flagship API manufacturing facility in Bidar, India (Unit IV). The Phase I of PB-11, with a capacity of 110 KL,...

Pharma Equity Groups datterselskab, Reponex Pharmaceuticals A/S, har fået godkendelse til at starte klinisk studie med RNX-011 mod livstruende peritonitis

at selskabet har modtaget myndighedsgodkendelse til at igangsætte et afgørende fase 2-studie med lægemiddelkandidaten RNX-011. Studiet skal undersøge behandling af sekundær peritonitis – en alvorlig og livstruende intra-abdominal infektion med høj...

CorrectSequence Therapeutics' CS-101 Achieves Promising Results in First Patient: High-Precision Base Editing Clinical Treatment for Sickle Cell Disease

the successful treatment of the first sickle cell disease (SCD) patient using its high-precision base-editing therapy CS-101. The breakthrough was achieved in an Investigator-Initiated Trial (IIT) conducted in collaboration with the First...

2025 Interim Results and Business Updates Announced by Innovent

and successful commercial launch across our general biomedicine portfolio, we have expanded our product portfolio to 16 drugs and achieved a notable improvement in revenue and profitability, maintaining strong business momentum. On the innovation...

Gvoke VialDx™ (glucagon injection) Launched by American Regent

patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure....

Innovent Biologics announces U.S. FDA IND approval for Phase 3 MarsLight-11 study of IBI363 in squamous NSCLC

(FDA) has cleared the investigational new drug (IND) application to initiate a global Phase 3 clinical trial (MarsLight-11) of IBI363 in immunotherapy(IO)-resistant squamous non-small cell lung cancer (NSCLC). IBI363 is Innovent's self-discovered...

Theravance Biopharma completes enrollment in Phase 3 CYPRESS study of Ampreloxetine for neurogenic orthostatic hypotension

Medicine at NYU Grossman School of Medicine. "Ampreloxetine is designed to address the underlying cause of nOH. In Study 0170, it showed compelling improvement in OHSA composite score without worsening supine hypertension.1 If these benefits are...

VASTHERA Receives U.S. FDA Clearance to Begin Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VTB-10, its drug candidate for pulmonary arterial hypertension (PAH), a rare, life-threatening disease...

CollPlant Biotechnologies Reports Second Quarter 2025 Financial Results and Provides Corporate Update

repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with...

GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

effective today. This collaboration significantly lowers the price available on GoodRx for two of the most in-demand GLP-1 medications nationwide, expanding access for those who lack adequate insurance coverage. Today also marks the first time...